Clinical Trials Browser

Head and Neck Neoplasms, Nasopharyngeal Neoplasms

NCT07325539 2026-05-22

LIGHT

Phase 2 Recruiting

55 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06378177 2026-05-19

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Active not recruiting

64 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06277050 2026-05-15

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

264 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05340491 2026-05-11

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Phase 3 Recruiting

212 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06323239 2026-05-11

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Phase 2 Recruiting

148 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07555860 2026-04-29

Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

28 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07209189 2026-04-23

(NeoScorch HN)

Phase 2 Recruiting

75 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT07540390 2026-04-22

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

Phase 3 Not yet recruiting

442 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07423078 2026-04-13

WOLF

Phase 2 Recruiting

87 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT06457503 2026-04-06

TRANSPARENT

Phase 4 Recruiting

100 enrolled

Head & Neck

Nasopharyngeal Neoplasms

NCT07320963 2026-03-20

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Phase 1/2 Not yet recruiting

52 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05635643 2026-03-19

Study of CHS-114 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

87 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

Clinical Trials

EDS01 HN

LIGHT

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

(NeoScorch HN)

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

WOLF

TRANSPARENT

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Study of CHS-114 in Participants With Advanced Solid Tumors